Posts Tagged ‘liraglutide’

More Steady Progress on Obesity Drugs

June 25, 2017 — This past week saw three bits of steady progress on the new generation of obesity drugs: lorcaserin, liraglutide, and semaglutide. It’s all movement in the right direction. Lorcaserin Cardiovascular Outcomes Study Progressing Nicely A huge cardiovascular outcomes study is underway with 12,000 patients receiving either lorcaserin (Belviq) or a placebo. The goal is to learn […]

A Steady Climb in Obesity or a Blockbuster Breakthrough?

April 29, 2017 — Making progress in obesity care continues to be a slow and steady business. Nearly 100 million Americans have this complex chronic disease. But it’s so stigmatized that most people don’t really want to think about it – let alone seek care. But progress continues, with a steady climb on all fronts. News from Novo Nordisk – now […]

Liraglutide for Obesity Looking Like Diabetes Prevention

February 23, 2017 — An impressive new three-year study of 3 mg liraglutide for obesity (Saxenda) finds that this therapy provides a large reduction in the risk of developing diabetes in people who have prediabetes. Published yesterday in Lancet, investigators found an 80% reduction in the risk of progressing to diabetes. In a post-hoc analysis, they made further assumptions […]

A Rough Ride Despite Saxenda’s Success

October 31, 2016 — Over the last four years, four new obesity meds gained approval and only one lived up to expectations in the marketplace – the Saxenda brand of liraglutide 3 mg from Novo Nordisk. The company reported quarterly results last week. Saxenda sales, growing impressively, are on track to surpass $200 million for the year. Net profit for […]

Liraglutide Gains Momentum as Others Struggle in Obesity

July 11, 2016 — Now in the second year since approval of liraglutide for treating obesity, a pattern is becoming clear. While other obesity drugs struggle, liraglutide gains momentum. The momentum is evident in growing prescriptions for Saxenda (the brand name for liraglutide sold by Novo Nordisk at the dose for obesity). For the second quarter of 2016, total prescriptions for Saxenda […]

A Beauty Contest for Obesity Meds in JAMA

June 17, 2016 — A new study published this week in JAMA provides useful perspective on the safety and efficacy of the newer obesity meds now available for managing the chronic disease of obesity. Rohan Khera and colleagues integrated the results for 29,018 patients in 28 published clinical trials and concluded: Among overweight or obese adults, orlistat [Alli, Xenical], […]

Longer Lives with Weight-Sparing Diabetes Care

June 14, 2016 — A quiet revolution is taking shape in the form of weight-sparing diabetes care that helps people live longer. Yesterday new data were simultaneously published in the New England Journal of Medicine and presented at the American Diabetes Association (ADA) Scientific Sessions. The LEADER study showed that people treated for type 2 diabetes with liraglutide (Victoza) were 15% less […]

Elusive Billions for Obesity Care

May 2, 2016 — A recent headline in Wired shouted it out: “Diabetes drug that also treats obesity could make billions.” What followed was a mostly reasonable discussion of the risks and benefits of obesity treatment in the jocular tone typical of Wired. Alexa Kurzius explains her assessment of the potential for Saxenda (liraglutide) for obesity: Initially, weight loss was just […]

Calming the Brain’s Response to Food

April 4, 2016 — Your brain’s response to food is one of the key tools that your body uses to protect you from starving or losing too much weight. Even bad food starts looking really good and thoughts about food crowd out everything else in the brain. In a featured presentation at ENDO 2016, Olivia Farr and colleagues demonstrated that […]

Liraglutide CV Outcomes: A Milestone for Diabetes and Obesity

March 7, 2016 — A major new study shows that people treated with liraglutide for type 2 diabetes have fewer strokes, heart attacks, and deaths from heart disease. Six years ago, cardiovascular outcomes had doctors scratching their heads about diabetes and obesity drugs. A hearing on a flawed outcome study with sibutramine resulted in its withdrawal from the market. […]